We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AI tools and visualization features aim to streamline radiology workflows.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced that the FDA has granted 510(k) clearance for View, a next-generation diagnostic imaging viewer within its Genesis Radiology Workspace.
For investors, the clearance strengthens GE HealthCare’s enterprise imaging portfolio and reinforces its push into cloud-based healthcare IT solutions. The development could support broader adoption of the Genesis Radiology Workspace across healthcare systems, potentially driving recurring software and services revenue.
As hospitals increasingly prioritize workflow efficiency and digital imaging platforms, this regulatory milestone may also enhance GEHC’s competitive positioning in the medical imaging software market.
Likely Trend of GEHC Stock Following the News
Following the announcement, shares of GEHC gained 1.8% at yesterday’s closing. Over the past six months, shares of the company have lost 0.5% compared with the industry’s 17.5% decline. However, the S&P 500 has risen 4.1% during the same time frame.
In the long term, the FDA clearance for View could strengthen GE HealthCare’s position in the fast-growing enterprise imaging and healthcare IT market. By enabling cloud-native, anywhere-access diagnostic imaging with integrated AI and advanced visualization, the solution can make GEHC’s Genesis Radiology Workspace more attractive to hospitals seeking to modernize radiology workflows. Greater adoption of this platform could expand GEHC’s installed base and drive higher-margin recurring revenue from software, upgrades, and related digital services, supporting more stable and scalable growth over time.
GEHC currently has a market capitalization of $33.85 billion.
Image Source: Zacks Investment Research
More on the News
View is a next-generation diagnostic imaging viewer developed as a core component of GE HealthCare’s Genesis Radiology Workspace. Designed as a zero-footprint, cloud-native solution, the platform allows radiologists to access diagnostic images directly through a web browser without the need for specialized on-site hardware or software installations. This architecture enables clinicians to securely review imaging data from virtually any location, supporting remote collaboration and faster clinical decision-making. The system is built to handle high-performance 2D and 3D image visualization, enabling radiologists to analyse complex scans efficiently while maintaining diagnostic accuracy.
Technologically, View integrates AI-enabled tools and advanced visualization applications within a unified workflow, allowing radiologists to move seamlessly between image viewing, analysis and reporting. The platform is also designed to reduce time spent on non-interpretive tasks, such as loading images or navigating multiple interfaces, which can significantly improve radiology productivity.
The FDA clearance is expected to strengthen GE HealthCare’s Enterprise Imaging and digital healthcare solutions portfolio, an increasingly strategic area as healthcare providers shift toward cloud-based imaging infrastructure. By enhancing the capabilities of the Genesis Radiology Workspace, the company can deepen its footprint in hospital IT ecosystems and expand opportunities for software-driven, recurring revenue streams.
Industry Prospects Favoring the Market
Going by the data provided by Mordor Intelligence, the global enterprise imaging market is valued at $2.02 billion in 2026 and is expected to witness a CAGR of 11.5% through 2031.
Factors like the increasing prevalence of chronic diseases, advancements in imaging quality and high-strength applications, the growing adoption by medical professionals, the rising R&D investments and the new product launches are boosting the market’s growth.
Other News
GE HealthCare recently introduced the latest generation of its LOGIQ general imaging ultrasound portfolio, including the LOGIQ E10 Series, LOGIQ Fortis and LOGIQ Totus. The systems feature the company’s Verisound Digital architecture and AI-enabled capabilities designed to enhance image clarity, streamline workflows and strengthen diagnostic confidence across a wide range of clinical applications.
Additionally, GE HealthCare secured FDA 510(k) clearance for three MRI innovations: SIGNA Sprint with Freelium, a sealed 1.5T magnet system; SIGNA Bolt, a high-performance 3T scanner; and SIGNA One, an AI-powered workflow platform that optimizes MRI processes. The company also expanded its partnership with BARDA through a $35 million contract focused on advancing AI-enabled ultrasound and next-generation imaging solutions for trauma care and mass-casualty preparedness.
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC has a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 14% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
Phibro Animal Health, currently sporting a Zacks Rank #1, reported fiscal second-quarter 2025 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 26.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2, reported second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.1% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
GEHC Wins FDA 510(k) Approval for View, Enhances Radiology Workflows
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced that the FDA has granted 510(k) clearance for View, a next-generation diagnostic imaging viewer within its Genesis Radiology Workspace.
For investors, the clearance strengthens GE HealthCare’s enterprise imaging portfolio and reinforces its push into cloud-based healthcare IT solutions. The development could support broader adoption of the Genesis Radiology Workspace across healthcare systems, potentially driving recurring software and services revenue.
As hospitals increasingly prioritize workflow efficiency and digital imaging platforms, this regulatory milestone may also enhance GEHC’s competitive positioning in the medical imaging software market.
Likely Trend of GEHC Stock Following the News
Following the announcement, shares of GEHC gained 1.8% at yesterday’s closing. Over the past six months, shares of the company have lost 0.5% compared with the industry’s 17.5% decline. However, the S&P 500 has risen 4.1% during the same time frame.
In the long term, the FDA clearance for View could strengthen GE HealthCare’s position in the fast-growing enterprise imaging and healthcare IT market. By enabling cloud-native, anywhere-access diagnostic imaging with integrated AI and advanced visualization, the solution can make GEHC’s Genesis Radiology Workspace more attractive to hospitals seeking to modernize radiology workflows. Greater adoption of this platform could expand GEHC’s installed base and drive higher-margin recurring revenue from software, upgrades, and related digital services, supporting more stable and scalable growth over time.
GEHC currently has a market capitalization of $33.85 billion.
Image Source: Zacks Investment Research
More on the News
View is a next-generation diagnostic imaging viewer developed as a core component of GE HealthCare’s Genesis Radiology Workspace. Designed as a zero-footprint, cloud-native solution, the platform allows radiologists to access diagnostic images directly through a web browser without the need for specialized on-site hardware or software installations. This architecture enables clinicians to securely review imaging data from virtually any location, supporting remote collaboration and faster clinical decision-making. The system is built to handle high-performance 2D and 3D image visualization, enabling radiologists to analyse complex scans efficiently while maintaining diagnostic accuracy.
Technologically, View integrates AI-enabled tools and advanced visualization applications within a unified workflow, allowing radiologists to move seamlessly between image viewing, analysis and reporting. The platform is also designed to reduce time spent on non-interpretive tasks, such as loading images or navigating multiple interfaces, which can significantly improve radiology productivity.
The FDA clearance is expected to strengthen GE HealthCare’s Enterprise Imaging and digital healthcare solutions portfolio, an increasingly strategic area as healthcare providers shift toward cloud-based imaging infrastructure. By enhancing the capabilities of the Genesis Radiology Workspace, the company can deepen its footprint in hospital IT ecosystems and expand opportunities for software-driven, recurring revenue streams.
Industry Prospects Favoring the Market
Going by the data provided by Mordor Intelligence, the global enterprise imaging market is valued at $2.02 billion in 2026 and is expected to witness a CAGR of 11.5% through 2031.
Factors like the increasing prevalence of chronic diseases, advancements in imaging quality and high-strength applications, the growing adoption by medical professionals, the rising R&D investments and the new product launches are boosting the market’s growth.
Other News
GE HealthCare recently introduced the latest generation of its LOGIQ general imaging ultrasound portfolio, including the LOGIQ E10 Series, LOGIQ Fortis and LOGIQ Totus. The systems feature the company’s Verisound Digital architecture and AI-enabled capabilities designed to enhance image clarity, streamline workflows and strengthen diagnostic confidence across a wide range of clinical applications.
Additionally, GE HealthCare secured FDA 510(k) clearance for three MRI innovations: SIGNA Sprint with Freelium, a sealed 1.5T magnet system; SIGNA Bolt, a high-performance 3T scanner; and SIGNA One, an AI-powered workflow platform that optimizes MRI processes. The company also expanded its partnership with BARDA through a $35 million contract focused on advancing AI-enabled ultrasound and next-generation imaging solutions for trauma care and mass-casualty preparedness.
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC has a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 14% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
Phibro Animal Health, currently sporting a Zacks Rank #1, reported fiscal second-quarter 2025 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 26.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2, reported second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.1% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.3%.